<Axsome Therapeutics (NASDAQ: AXSM) surged 16% year-to-date, outperforming the S&P 500’s 11% gain, fueling growing confidence among Wall Street analysts about further upside. The stock’s average price target of $285.42 suggests nearly 37% potential upside from its current level. This post indicates why market leaders view the biotech firm as a compelling buy despite near-term headwinds.[/A]

<Axsome Theraputics’ recent financial results reflect solid clinical and regulatory momentum. The company secured FDA approval for Auvelity as a treatment for depression and recently expanded its label to cover Alzheimer’s disease (AD) agitation. Its approved portfolio also encompasses Symbravo, targeting migraines, and Sunosi, which addresses daytime sleepiness associated with narcolepsy. Revenue is accelerating—second‑quarter earnings rose 46% year‑over‑year to $218.4 million, driven primarily by Auvelity, which posted $180.3 million in net product sales, up 51% from the prior year.
It contributed $180.3 million in net product sales, up 51% compared to the year‑ago period. The good news is that Auvelity’s indication in AD agitation is still brand‑new. The U.S. Food and Drug Administration granted it in April. As the medicine gains traction in this market, it will boost sales and unlock significant addressable opportunities—more than five million Americans live with AD‑related agitation, and treatment options remain limited.[Continue reading][/continue]The company’s robust pipeline provides multiple catalysts for continued growth. Next-generation candidates include AXS‑12, an investigational medicine for cataplexy in narcolepsy that has completed Phase 3 trials and is currently under U.S. regulatory review. Underestimating the scale, Axsome Therapeutics projects AXS‑12 could generate $500 million to $1 billion in narcolepsy revenue.
Other promising assets feature in active or late‑stage development: AXS‑14 targets fibromyalgia (late‑stage trials), AXS‑20 focuses on schizophrenia (ongoing development), and additional pipelines are in various phases. Collectively, Axsome’s forward‑looking pipeline could push peak company sales beyond $16 billion by 2040.
Assuming a realistic 3× price‑to‑sales multiple given the biotech sector, reaching $16 billion in revenue by 2040 would translate to a $48 billion market capitalization—a compound annual growth rate of roughly 11.1% over the next 14 years. This strong upside perspective underpins Wall Street’s bullish outlook and supports the argument for adding to existing positions.[Learn more about the investment thesis][/futureProspects]While risks persist—including the possibility of clinical or regulatory setbacks with any single pipeline asset, intense competition in high‑growth therapeutic areas like depression—Axsome also retains several earlier‑stage candidates that could add further value. The company’s broad and deep pipeline, combined with accelerating demand for treatments in narcolepsy, Alzheimer’s disease, migraines, and more, creates a compelling case for sustained investor interest.

Should You Buy Axsome Therapeutics Now?

When evaluating whether to invest, consider the following key factors: The Motley Fool analyst team highlighted Axsome Therapeutics as one of ten standout growth picks in their long‑term stock list. With a track record of consistently beating the S&P 500 by nearly fivefold, the fund aims to provide both high upside potential and established fundamentals.

While past performance demonstrates exceptional returns—such as Netflix expanding from $1,000 to $429,223 and Nvidia from $1,000 to $1,317,883 in a short window—these examples underscore the kind of explosive growth possible when identifying undervalued biotech companies early. Today’s valuation remains reasonable relative to peer comparisons, and the combination of imminent pipeline milestones, regulatory approvals, and a clear path to $16 billion in annual revenue makes this a compelling addition to a diversified portfolio focused on innovation‑driven growth.

Conclusion: Despite the inherent risks outlined, Axsome Therapeutics possesses a durable narrative grounded in medical need, scientific advancement, and a powerful pipeline. By 2040, realization of its full commercial potential could reposition the company at a substantial multi‑billion dollar valuation, offering investors meaningful long‑term upside if execution stays within reach.

p(S.13) — Disclaimer: The Motley Fool does not hold positions in the stocks mentioned. The Motley Fool has positions in Axsome Therapeutics.

Original Publication: Axsome Therapeutics Stock Is Up 16% Year to Date. Why Wall Street Thinks It Has Even More Room to Run
Posted by The Motley Fool

Note: All media elements (including the logometric GIF and caption) have been preserved unchanged per protocol.

Source link